Liquidia Corp — Form 8-K
Filed October 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Liquidia settled six pending lawsuits with United Therapeutics (UTC) for a net payment of $380.7M: $175M upfront within 30 business days, plus $145.4M in two equal installments (Jan & Apr 2027). Liquidia also paid $60.3M to resolve interests of Sandoz, Henderson SPV, and PBM in antitrust litigation. Liquidia removes PH-ILD indication from YUTREPIA label, ceases PH-ILD promotion, and retains unrestricted right to sell YUTREPIA for PAH. Q3 2026 YUTREPIA sales were $222.7M; cash position $396.1M as of Sept 30, 2026.
Why this rating
Material settlement cost (~45% of company market cap) paired with business continuity. Removes litigation risk but constrains YUTREPIA to PAH only; generates near-term cash outflow but preserves revenue stream and ongoing operations.
Price action (we called it neutral)
at our read · unknown $36.26 | +10 min · unknown $37.25 ▲ 2.74% | +30 min · unknown $35.62 ▼ 1.75% | +1 hr · unknown $34.41 ▼ 5.09% | +4 hrs · unknown $33.99 ▼ 6.25% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.